Natalia Carballo, MD Sanitas Hospitals/Atrys Health Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of t...
All content for ACE OncoCast is the property of ACE Oncology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Natalia Carballo, MD Sanitas Hospitals/Atrys Health Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of t...
Expert Interview of Specialist Insights in Urothelial Cancer: Molecular Pathology and Biology of Urothelial Cancer
ACE OncoCast
15 minutes
1 year ago
Expert Interview of Specialist Insights in Urothelial Cancer: Molecular Pathology and Biology of Urothelial Cancer
Francisco X. Real, MD, PhD National Cancer Research Center Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the re...
ACE OncoCast
Natalia Carballo, MD Sanitas Hospitals/Atrys Health Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of t...
